Recent studies have shown that orphan GPCRs of the GPR family are utilized as specialized chemosensors in various tissues to detect metabolites, and in turn to activate downstream pathways which regulate systemic homeostasis. These studies often find that such metabolites are generated by well-known metabolic pathways, implying that known metabolites and chemicals may perform novel functions. In this review, we summarize recent findings highlighting the role of deorphanized GPRs in renal development and function. Understanding the role of these receptors is critical in gaining insights into mechanisms that regulate renal function both in health and in disease.
Recent studies have highlighted the key roles that classical sensory receptors, such as olfactory receptors and taste receptors, play in whole-body physiology. Although a functional role for these sensory receptors outside of the nose and tongue did not begin to emerge until~2003 (Spehr et al. 2003) , it is now well appreciated that both olfactory and taste receptors are expressed in a variety of other tissues, where they act as sensitive and selective chemoreceptors to influence physiological processes (Spehr et al. 2003 , Feldmesser et al. 2006 , Huang et al. 2006 , Griffin et al. 2009 , Pluznick et al. 2009 , Shah et al. 2009 , Bryksin & Matsumura 2010 , Kang & Koo 2012 , Pluznick & Caplan 2012 , Pluznick 2013 , Busse et al. 2014 , Wu et al. 2015 . For example, the sour taste receptor also functions as a pH sensor in the spinal column (Huang et al. 2006) , sweet taste receptors are expressed in the gut (Dyer et al. 2005) and may be dysregulated in diabetes (Young et al. 2013) , and olfactory receptors play physiological roles in diverse tissues including the lungs (Shah et al. 2009 ), kidneys (Pluznick et al. 2009 and muscle (Griffin et al. 2009 ). Thus, although a role for olfactory and taste receptors in peripheral tissues is a nascent field, it is becoming clear that olfactory and taste receptors function in a variety of ways beyond their 'classic' roles in taste and smell.
Although physiological roles for sensory receptors (olfactory and taste) which are 'ectopically' expressed have been understudied until quite recently, the new and exciting functions outlined in the past~13 years highlight the fact that we have much to learn from these 'understudied' receptors. However, there is another class of sensory chemoreceptors, which is arguably even less studied: G-protein-coupled receptors of the 'Gpr' family. These receptors are a subset of the GPCR superfamily Class A and were all named with the prefix 'Gpr' (for G-protein (coupled) receptor) because at the time that they were named they were orphan receptors with no known ligand. Thus, their nomenclature is rather unique as the common prefix Gpr does not necessarily reflect a structural similarity within the GPCR superfamily, but rather a common lack of available information. Once a Gpr has been deorphanized (or 'adopted'), they are often renamed to reflect their known ligand (although many groups may continue to refer to them by the Gpr prefix). One can easily imagine that, for very practical reasons, the 'orphaned' status of these receptors is easily perpetuated, as orphan receptors are not often selected as the focus of a study, or as the best candidate for follow-up after a screen. Despite this, however, if one assays for expression in an unbiased fashion, many Gprs are highly expressed (Snead & Insel 2012 , Rajkumar et al. 2014 , and exciting and novel roles for specific members of the Gpr family have begun to emerge in recent years.
The focus of this review is a summary of what is currently known regarding the functional role of the Gpr family members in the kidney. The kidney plays a key and pivotal role in the regulation of homeostasis, monitoring the concentration of a wide variety of substances in both the blood and in the forming urine; thus, we have a particular interest in how the kidney may utilize novel chemoreceptors in order to maintain homeostasis. In addition, many GPCRs are excellent drug targets (Overington et al. 2006 , Lundstrom 2009 , Rask-Andersen et al. 2014 , Insel et al. 2015 , further increasing the promise of the understudied Gpr family. Here, we will review what is known in the literature regarding renal Gpr receptors, primarily highlighting receptors which have now been deorphanized (adopted) and for which some function has been assigned ( Fig. 1; Table 1 ). We hope that this review will summarize the current state of the field, while also highlighting the promise of this unique and understudied area.
Gpr30 (Adopted name: GPER)
Gpr30, which is also known as G-protein-coupled estrogen receptor 1, or GPER, was initially deorphanized by two groups in 2005 as an estrogen receptor (Revankar et al. 2005 , Thomas et al. 2005 . Gpr30 has been reported to couple to a number of signalling pathways including Ca 2+ , adenylyl cyclase, transactivation of epidermal growth factor receptors (EGFRs), phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinases (MAPKs) (Prossnitz et al. 2007 ,
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Macula Densa (GPR91) Figure 1 Schematic illustration of the localization of GPRs in the kidney. Nephron segments are labelled and the GPRs that have been shown to be present in each segment are listed. Ge et al. 2012 , Luo et al. 2012 , Wei et al. 2014 . In studies beginning in~2011, evidence has suggested that Gpr30/GPER may also be responsive to aldosterone , Wendler & Wehling 2011 , Briet & Schiffrin 2013 , Ren et al. 2014 , De Giusti et al. 2015 , Orlowski et al. 2016 , although there is no clear agreement on whether aldosterone is truly a ligand for Gpr30 (summarized in Barton (2012) ; also, see discussion of Cheng et al. (2014) below). What is clear, however, is that Gpr30 signalling intersects with renal physiology , Batenburg et al., 2012 . Gpr30 has been reported to localize to a number of segments in the mouse kidney by immunohistochemistry (with antibody fidelity being confirmed by competing signal with the immunogenic peptide) (Cheng et al. 2014) . According to the Cheng et al. study, Gpr30 is expressed primarily in the distal convoluted tubule (DCT) and loop of Henle, with lower expression in the proximal tubule and absent expression in the collecting ducts. This same study also showed that both the level of expression (Western blot) and the subcellular localization of Gpr30 are modified by the oestrous cycle. Finally, this study additionally used plasma membrane fractions from both whole kidney and from cells overexpressing Gpr30 to assay [ 3 H] ligand binding (of estrogen and aldosterone). Taking advantage of the fact that Gpr30 localizes to the plasma membrane, whereas the canonical aldosterone receptor, the mineralocorticoid receptor (MR), is intracellular, they found that plasma membrane fractions bound to estrogen, while the cytosolic fraction (but not the plasma membrane fraction) bound to aldosterone. Thus, they side with the view that GPER does not function as a membrane aldosterone receptor.
With regard to functional roles for Gpr30 in renal physiology, although estrogen has been found to be renoprotective after ischaemia-perfusion, it appears that this effect is not dependent upon Gpr30 (Hutchens et al. 2014) -curiously, the same study noted that Gpr30 knockout (KO) animals tend to have reduced plasma creatinine, a topic which certainly deserves further inquiry. A separate study, which used a GPER agonist and GPER knockdown rather than transgenic animals, implied that Gpr30 does mediate beneficial effects of estrogen in cultured mesangial cells (by influencing TGF-b1 signalling) (Li et al. 2014) . Finally, in another study, it was demonstrated (Hofmeister et al. 2012) 
Gpr41 and 43 (Adopted name: Ffar3 and Ffar2)
Gpr41 and Gpr43 are relatively well-studied Gprs, although little is known about their roles in the kidney. In 2003, two different groups reported that these two GPCRs are receptors for short-chain fatty acids (SCFAs) , Le et al. 2003 , and thus, they were renamed free fatty acid receptor 3 (Ffar3, Gpr41) and free fatty acid receptor 2 (Ffar2, Gpr43). Both Gpr41 and Gpr43 couple to G i , Le et al. 2003 , although Gpr43 has additionally been reported to couple to G q , Le et al. 2003 . Much of the interest in these two Gprs was driven by the fact that their ligands, SCFAs, are a by-product of gut microbial metabolism (Bugaut 1987) . In fact, although SCFAs are found in the micromolar range in the plasma, they are virtually undetectable in the plasma of germ-free mice (mice without any microbiota) (Perry et al. 2016) . Thus, there has been great interest in Gpr41 and Gpr43 as mediators of microbe-host communication, with studies showing that microbial SCFAs interact with these receptors to mediate various aspects of host physiology, notably adiposity/metabolism (Samuel et al. 2008 ) and inflammation/immune responses (Maslowski et al. 2009 ).
With regard to renal function, both Gpr41 (Rajkumar et al. 2014) and Gpr43 are known to be expressed in the kidney (both are in the renal artery by RT-PCR; other renal localization not yet examined). These receptors are also present in extrarenal blood vessels , and SCFAs delivered intravenously produce an acute hypotensive effect in mice. This hypotensive response to SCFAs is blunted in Gpr41 KO animals, indicating that Gpr41 mediates the bulk of this hypotensive response . In future studies, it will be important to more precisely localize Gpr41 and Gpr43 within the kidney, and to better outline the functional roles of each of these receptors.
Gpr48 (Adopted name: Lgr4)
Gpr48 (also known as LGR4) is part of the type B leucine-rich repeat containing GPCRs (LGRs), with 17 leucine-rich repeats in its extracellular domain (Loh et al. 2001) . Gpr48 is expressed in several human and mice tissues such as the kidneys, reproductive system, eye, colon, bladder, and pancreas, as well as in certain tumours (Loh et al. 2001 , Styrkarsdottir et al. 2013 , Yi et al. 2013 . Gpr48 knockdown causes reduced viability and severe defects in several organs in mice, indicating that GPR48 plays an intricate role during development. In 2011, three different groups showed that the secreted R-spondin proteins, which are agonists of Wnt/b-catenin signalling, are strong ligands for Gpr48 and also for a closely related receptor LGR5 (Carmon et al. 2011 , Glinka et al. 2011 , de Lau et al. 2011 .
In the kidneys, Gpr48 is expressed highly in the cortex with localization seen primarily in the proximal tubules and moderate expression in some DCTs but none in the glomeruli (Van et al. 2005 , Yi et al. 2013 . Several groups have generated whole animal Gpr48 KO mice with distinct gene-targeting strategies to investigate its role in the kidney. In 2006, Kato et al. reported that Gpr48 KO mice were born at a significantly reduced rate than expected Mendelian frequencies (Kato et al. 2006) . They also noticed that Gpr48 null pups showed a notable decrease in the number and density of glomeruli at P0 and survived only until P2, exhibiting renal hypoplasia, premature ureteric bud differentiation and increased plasma creatinine levels. In this paper, the authors noted that the Gpr48 null pups failed to nurse (Kato et al. 2006) , which is a known cause of neonatal death. Failure to nurse may be due to a defective functional role of Gpr48 in the olfactory epithelium and vomeronasal organ, (Van et al. 2005) as nursing in mice is strongly mediated by olfaction (Belluscio et al. 1998 , Wong et al. 2000 . As the mice on this study were still on a mixed background, the same group subsequently followed this work by backcrossing the Gpr48 KO mice at least 10 times onto C57BL/6J and noticed that the Gpr48 null mice exhibited an even more severe phenotype, with renal hypoplasia and cysts observed as early as E16.5 (Mohri et al. 2011) . In agreement with this, other groups have also shown that Gpr48 KO mice exhibit an increased rate of apoptosis in their kidneys, with a reduced expression level of anti-apoptotic factor PAX2 (Mohri et al. 2012) . This increase in apoptosis has been hypothesized to cause the observed renal hypoplasia in these Gpr48 KO animals.
In 2014, another Gpr48 KO model was generated and its role in renal development and the cause for cysts in their kidneys were investigated (Dang et al. 2014 ). In agreement with previous studies, these authors also noted significant perinatal death (~60% of pups died between P0 and P1) in Gpr48 KO mice but they found that through breeding and cross-breeding they could reduce embryonic or neonatal lethality. The average kidney size of the Gpr48 KO mice was drastically smaller compared with that of the agematched WT littermates. In addition, severe polycystic lesions were observed in~70% of Gpr48 KO mice (that are past 5 weeks old), along with upregulation of severe fibrotic markers such as connective tissue growth factor, fibronectin and alpha-smooth muscle actin in both the mRNA and protein levels. Normally, with such a high polycystic burden the KW/BW ratio is higher than controls, but in the case of Gpr48 KO animals the KW/BW ratio is still lower than control mice. This intriguing finding can be attributed to the severe renal hypoplasia observed in the Gpr48 KO animals. Furthermore, the authors found that the expression level of both PKD1 and PKD2, genes responsible in formation of polycystic kidney disease (PKD) (Harris 1999) , was significantly weaker in Gpr48 KO animals compared with controls. Simultaneously, they also noticed that signalling molecules involved in the b-catenin/Wnt pathway (also implicated in PKD) (Lal et al. 2008) were upregulated in Gpr48 KO mice. Together, these results strongly implicate Gpr48 in playing an important role in renal development and demonstrate that deletion of Gpr48 results in severely undersized multicystic kidneys through altered expression levels of PDK1/PDK2 and the b-catenin/Wnt pathway.
Gpr4
In 2003, Ludwig et al. elegantly demonstrated that two orphan GPCRs, Gpr4 and GPR68 (OGR1), respond to changes in extracellular pH (Ludwig et al. 2003) and are not activated by lipids, such as lysophosphatidylcholine (LPC) or sphingosylphosphorylcholine (SPC), as has been previously postulated (Zhu et al. 2001) . This revealed for the first time that protons can serve as ligands for GPCRs and showed (through site-directed mutagenesis) that histidines at key extracellular sites are critical for sensing pH in these GPCRs (Ludwig et al. 2003) . We now know that two other GPCRs, GPR65 (TDAG) and GPR132 (G2A), also belong to this unique family of pH-sensing GPCRs (Murakami et al. 2004 , Ishii et al. 2005 . Although these four GPCRs are expressed in various tissues, GPR4 is the only one among this group of pH-sensing GPRs that is highly present in the kidney (Sun et al. 2010) .
In the kidneys, GPR4 mRNA is detected primarily in the collecting ducts and has been shown to elevate cAMP levels in OMCD cells in vitro in response to acidic pH stimuli (Sun et al. 2010) . The role of GPR4 in the kidney was further elucidated when it was noted that GPR4 KO mice exhibit impaired net acid excretion (NAE) in the urine, resulting in disruption of systemic acid-base homeostasis. When the bloodgas parameters were analysed in nonanaesthetized mice, GPR4 KOs exhibited nongap metabolic acidosis with lower bicarbonate and CO 2 levels compared with WT mice. Despite metabolic acidosis, GPR4 KO mice had increased urinary pH. This phenotype agrees well with the GPR4 localization in the collecting duct, as it is a major site for acid-base regulation in the kidneys. Furthermore, the cell-type composition of intercalated cells (ICs) in the collecting ducts were also found to be altered in the GPR4 KO mice, with an increased number of A-ICs and reduced number of B-ICs and non-A-non-B cells in GPR4 KOs compared with WT (Sun et al. 2015) .
Surprisingly, GPR4 deletion in mice increases the expression level of calcium-sensing receptor (CASR) by twofold in the kidney, both at baseline and also during acidic challenge. This intriguing finding strengthens the potential involvement of CASR in renal acid-base regulation and tightens the link between systemic calcium and pH homeostasis (Sun et al. 2015) . In addition, GPR4 expression is also seen in vascular endothelial and smooth muscle cells, brain, lungs, heart and liver , Mahadevan et al. 1995 , Lum et al. 2003 , Kim et al. 2005 , where its functional role is not yet completely understood.
Gpr91 (Adopted name: Sucnr1)
In 2004, He et al. reported that the orphan receptor GPR91 is activated by extracts from pig kidneys (He et al. 2004) . By performing mass spectrophotometric analysis of the extract, they found that the natural ligand for GPR91 is succinic acid. Succinate is an intermediate of TCA cycle, and thus, this study showed that metabolites of major cellular pathways can serve as ligands for orphan GPRs, and highlights the potential for GPRs and related metabolites to be involved in regulation of critical physiological functions beyond their traditional roles. This same study also showed that the closely related Gpr99 receptor responds to another TCA cycle intermediate alphaketoglutarate (Gpr99 will be discussed in detail in the next section).
The basal plasma level of succinate is 1-20 lM, but it has been shown to increase locally when a tissue's supply and demand for energy is not met, commonly encountered during conditions such as hypoxia, oxidative stress, ischaemia, hypertension and diabetes (Hebert 2004 , Koivunen et al. 2007 , Sadagopan et al. 2007 ). In such instances, succinate from the mitochondria is released into the systemic circulation, which elevates plasma succinate levels in the range of the EC 50 value of GPR91 (30-60 lM) (Toma et al. 2008) . In addition to high expression in the kidneys, Gpr91 is additionally seen in the liver, blood vessels, white adipose, and in a variety of other tissues (Correa et al. 2007 , Regard et al. 2008 , Rubic et al. 2008 , Sapieha et al. 2008 , Hakak et al. 2009 , Hamel et al. 2014 where it has been thought to sense succinate, serve as an indicator of mitochondrial stress, and activate downstream physiological mechanisms to regulate homeostasis.
In the initial paper, He et al. detected GPR91 mRNA levels in various nephron segments and juxtaglomerular apparatus (JGA) by RT-PCR and in situ hybridization (He et al. 2004) . Furthermore, they demonstrated that intravenous administration of succinate induces hypertension in rodents, caused by renin-initiated activation of renin-angiotensin system. Subsequently, GPR91 expression has also been localized in two additional cell types: macula densa (MD) and glomerular endothelium (Toma et al. 2008 , Robben et al. 2009 ). In these cell types, GPR91 has been shown to play an intricate role in paracrine cross talk between distinct nephron segments via succinate, which results in renin release by the juxtaglomerular cells (Toma et al. 2008 . Future studies will no doubt continue to dissect this intrarenal communication mechanism, as GPR91-succinate-renin release appears to be involved in regulation of fluid, acid-base and blood pressure homeostasis.
Gpr99 (Adopted name: Oxgr1)
Gpr99 was first identified and found to be expressed in the kidney in 2002 (Wittenberger et al. 2002) . In 2004, the same paper that deorphanized Gpr91 (Sucnr1) as a succinate receptor also identified Gpr99 as a receptor for a-ketoglutarate (He et al. 2004 ); intriguingly, both ligands are intermediates in the citric acid cycle (also known as the Kreb's Cycle). It is well established that the proximal tubule handling of a-ketoglutarate is altered by changes in acid-base balance (Fig. 2) . Under normal or acidotic conditions, a-ketoglutarate is reabsorbed (primarily in the proximal tubule) (Ferrier et al. 1985 , Martin et al. 1989 ). However, under alkalotic conditions, net renal reabsorption is converted to net renal secretion as well as net production (Ferrier et al. 1985 , Martin et al. 1989 , Cheema-Dhadli et al. 2002 . Building on this finding, a study in 2013 (Tokonami et al. 2013) showed that these changes in a-ketoglutarate concentration are sensed by Gpr99, which is expressed in the intercalated cells later on in the connecting tubule and connecting duct (Tokonami et al. 2013 , Diehl et al. 2016 ). Thus, a-ketoglutarate signalling to its receptor later on in the nephron serves as an intrarenal and intratubule paracrine signalling mechanism (Allison 2013 , Peti-Peterdi 2013 , Tokonami et al. 2013 , Morla et al. 2016 . Intercalated cells are critical in the control of acid/base balance, and a-ketoglutarate signalling to Gpr99 in the intercalated cells is a mechanism to instruct the intercalated cells to activate pendrin and regulate HCO 3 À to combat the alkalosis.
Indeed, mice null for Gpr99 have an impaired ability to respond to an alkali load (Tokonami et al. 2013) . This study also demonstrated that a-ketoglutarate stimulates NaCl reabsorption via Gpr99 in intercalated cells (Tokonami et al. 2013) ,and likely also increases NaCl reabsorption in principal cells (in an Gpr99-independent manner). Gpr99 is thought to signal via G q (He et al. 2004) .
In 2015, an elegant study further expanded on this finding by studying SPAK KO mice; SPAK is a kinase which has been shown to regulate the activity of the sodium chloride cotransporter (NCC) in the DCT (McCormick et al., 2011 , Richardson et al., 2008 , Chiga et al., 2008 . In the absence of SPAK, NCC cannot be activated; thus, these mice can serve as a model to understand compensatory processes which occur with chronic treatment using thiazide diuretics (a commonly prescribed class of antihypertensive which inhibits NCC). SPAK KO mice exhibited an integrated compensatory mechanism involving both Gpr99 and a-ketoglutarate (Grimm et al. 2015 an increase in a-ketoglutarate synthesis in the proximal tubule, and a coordinate upregulation of Gpr99 in the intercalated cells. Thus, a paracrine intranephron mechanism was activated which facilities delivery of a-ketoglutarate to activate Gpr99 and stimulate NaCl reabsorption. This mechanism, then, offers a potential and intriguing insight into mechanisms which may ultimately limit the effectiveness of thiazide diuretics.
APJ -(Adopted name: APLNR)
The apelin receptor (APJ) was first identified by O'Dowd et al. in 1993 as an orphan GPCR (O'Dowd et al. 1993 . APJ closely resembled the angiotensin receptor AT1, with a 54% identity in the transmembrane regions, but APJ did not respond to angiotensin II. Five years later, APJ was deorphanized, when Tatemoto et al. showed that it responded to a 36-amino acid peptide from bovine stomach extract, which they named apelin (Tatemoto et al. 1998) . We now know that both apelin and APJ are detected in various tissues such as the CNS, heart, lungs and kidneys (Lee et al. 2000 , O'Carroll et al. 2000 , Medhurst et al. 2003 , Kleinz & Davenport 2004 , Hus-Citharel et al. 2008 where their role has been elucidated in several physiological and pathophysiological conditions involving regulation of immune functions, fluid homeostasis, bone physiology and embryonic development of the cardiovascular system . In the kidneys, RT-PCR experiments detect APJ mRNA at very high levels in the glomerulus with relatively moderate amounts in the proximal tubules to collecting ducts. In situ hybridization studies in rat kidneys also localized APJ receptor in the glomeruli, with additional labelling seen in the cells along the vasa recta in the inner stripe of outer medulla, and in the vascular wall of glomerular arterioles in both endothelial and vascular smooth muscle cells (O'Carroll et al. 2000 , Hus-Citharel et al. 2008 . The role of APJ in mechanisms involving renal fluid homeostasis was evident in APJ KO mice (Roberts et al. 2009 ). APJ KO mice have a significant defect in concentrating urine during water deprivation, as the urine output volume is not reduced like in that of WT mice. Normally, during conditions of water deprivation, plasma levels of arginine vasopressin (AVP, also known as antidiuretic hormone) increase and act on the V2 receptors in the kidneys. This results in antidiuresis due to increased levels of apical aquaporin channels in the collecting duct, resulting in reduced urine volume with increased osmolality. APJ KO mice show significant defects in concentrating urine during water deprivation, as the urinary volume is not reduced as it is in WT mice. The urine osmolality is also reduced in APJ KOs compared with WT mice. However, the plasma AVP levels were comparably increased during water deprivation in both WT and APJ KO mice, indicating that the neurosecretion of AVP to osmotic stress is still intact. However, during peripheral administration of dDAVP (a V2 receptor agonist), APJ KO mice showed a significantly attenuated increase in urine osmolality compared with WT mice, suggesting that the renal V2 receptor mediated response to circulating AVP levels is defective. In addition, in APJ KO mice the AVP mRNA levels were elevated in the PVN during basal conditions, and this level did not increase further during dehydration as observed in WTs. Together, it appears that APJ is necessary for a proper response to changes in AVP in the kidneys and regulating systemic fluid homeostasis.
In addition to their role in fluid homeostasis regulation, apelin and APJ have been implicated in renal fibrosis, renal ischaemia/reperfusion (I/R) injury and diabetic nephropathy. In the UUO-induced renal fibrosis mice model, both apelin and APJ mRNA levels are upregulated in the kidney, and this contributes to alleviating fibrosis by increasing the NO production in the endothelium through the Akt/eNOS pathway (Tatemoto et al. 2001) . Furthermore, recent studies have reported that the apelin-APJ system serves a renoprotective role in I/R injury and diabetic nephropathy. Apelin administration prior to the I/R surgery decreases plasma urea and creatinine levels and increases GFR in the rat model (Sagiroglu et al. 2012) . Also, apelin treatment has been shown to upregulate the levels of the antioxidant enzyme, catalase, in the kidneys. This improves recovery from renal and glomerular hypertrophy in the Ove26 diabetic mice model, independent of any action from the renin-angiotensin system (Day et al. 2013) .
Conclusions and future directions
Although we have focused here on receptors with known ligands and functions ( Fig. 1; Table 1 ), these few examples only serve to highlight how much is still to be learned in this area: indeed, there are many Gprs which are known to be expressed in the kidney, but whose ligands and/or functions remain unstudied. Several large-scale screens (Vassilatis et al. 2003 , Regard et al. 2008 for tissue expression of GPCRs have identified a number of GPCRs which are expressed in the kidney -in many cases, the functional role (and often the ligands) is unknown. We recently used a Taqman GPCR screen to perform a targeted study for Gprs in the kidney -as a result, we identified 76 renal Gprs (Rajkumar et al. 2014) . We were impressed to note that the most highly expressed Gprs were expressed at levels comparable to classic renal receptors including the angiotensin II receptor and the arginine vasopressin receptor (Rajkumar et al. 2014) , implying that renal Gprs may play important roles in renal physiology, and likely mediate a myriad of functions that are yet to be discovered. This is especially relevant in the light of the fact that GPCRs are generally a very druggable class: GPCRs are poised on the plasma membrane to respond to drugs in a cell type-specific manner, making them particularly enticing targets for therapeutics. In fact, it has been estimated that GPCRs represent~20-60% of current drug targets (Overington et al. 2006 , Lundstrom 2009 , Rask-Andersen et al. 2014 . As GPRs are classically understudied, it is our hope that uncovering the function of these unsung receptors can lead not only to a heightened understanding of renal physiology, but perhaps future treatments for renal disease.
